Drugs / Prodiax
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02225327 Comparator | Oct → Dec 2013 | influenza, pneumococcal infection | Korea University Guro Hospital | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Prodiax | “This study is intended to evaluate the immunogenicity and safety of concomitant MF59-adjuvanted trivalent influenza vaccine (MF59-aTIV, Fluad) and 23-valent pneumococcal...” NCT02225327 ↗ |
| Known as | PPV23 | “This study is intended to evaluate the immunogenicity and safety of concomitant MF59-adjuvanted trivalent influenza vaccine (MF59-aTIV, Fluad) and 23-valent pneumococcal...” NCT02225327 ↗ |
| Modality | Vaccine | “23-valent pneumococcal polysaccharide vaccine” NCT02225327 ↗ |